# Brain FAAH Binding Rises During Early Cannabis Abstinence in a Small PET Study > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-brain-faah-binding-rises-during-ear-2026-10-07/ > **Published:** 2026-10-07T23:11:02-04:00 | **Last Modified / Clinically Audited:** 2026-10-07T23:11:02-04:00 > **Clinical Summary:** medical cannabis research: Physician review of PET imaging of FAAH in chronic Cannabis users: longitudinal assessment during short-term abstinence.: evidence... --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of PET imaging of FAAH in chronic Cannabis users: longitudinal assessment during short-term abstinence.. Clinical Insight | CED Clinic Among 14 participants with cannabis use disorder who completed two PET scans, whole-brain FAAH binding increased approximately 10% between overnight abstinence and a later scan roughly 3 to 7 days after monitored last use. This is a biological signal, not a demonstrated treatment effect. Associations with baseline depression and impulsivity make mood assessment and structured follow-up clinically relevant, but the supplied abstract does not establish that FAAH changes caused withdrawal or predicted relapse. Clinicians should explain early withdrawal without implying permanent brain damage, assess coexisting psychiatric symptoms, and offer established behavioral support rather than adjust cannabis dosing based on these imaging findings. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Brain FAAH Binding Rises During Early Cannabis Abs. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42106478/) Table of Contents - [Brain FAAH Binding Rises During Early Cannabis Abstinence in a Small PET Study](#Brain_FAAH_Binding_Rises_During_Early_Cannabis_Abstinence_in_a_Small_PET_Study)[How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Brain FAAH Binding Rises During Early Cannabis Abstinence in a Small PET Study A small longitudinal PET study found increased brain FAAH binding during early cannabis abstinence. Associations with depression and impulsivity suggest research directions, but the findings do not establish a withdrawal treatment or predict relapse. What This Study Teaches Us In 14 paired-scan completers from 17 initially enrolled participants with cannabis use disorder, whole-brain FAAH binding increased approximately 10% from overnight abstinence to a later scan roughly 3 to 7 days after monitored last use (p = 0.003). The largest reported regional increase was in the ventral striatum (11%, p = 0.026), and whole-brain changes were associated with abstinence duration, baseline depression severity, and impulsivity. Why This Matters The findings identify a candidate biological pathway for studying early abstinence, while highlighting mood and impulsivity as relevant clinical assessment domains. They do not justify enzyme-directed self-treatment, PET-guided dosing, or claims that relapse can be predicted. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceNeuropsychopharmacology : official publication of the American College of NeuropsychopharmacologyPublication Date2026OctEvidence LevelJournal ArticleFocus AreaBrain FAAH Binding Rises During Early Cannabis Abstinence inLead AuthorsClaudia Poluga, Shahtaj S Dheda, Nadia Boachie, Tina McCluskey et al.DOI10.1038/s41386-026-02438-7PMIDPMID: 42106478 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** Hypothetical headline framing, not a verified media quotation: Scientists discover the brain enzyme that causes cannabis withdrawal and unlocks a new treatment. **Primary Journal Data:** Of 17 initially enrolled participants, 14 completed both scans. Whole-brain [11C]CURB FAAH binding increased approximately 10% during short-term abstinence (p = 0.003); the largest reported regional change was in the ventral striatum (11%, p = 0.026). Changes were associated with abstinence duration, baseline depression severity, and an impulsivity trait. No treatment intervention or relapse benefit is reported in the supplied abstract. **Dr. Caplan’s Clinical Verdict:** Preliminary evidence of an abstinence-associated imaging change, not proof of withdrawal causation or treatment efficacy. FAAH remains a research target rather than a clinically validated tool for selecting cannabis doses or managing withdrawal. Primary Analysis | PET imaging of FAAH in chronic Cannabis **Study Overview:** Cannabis withdrawal in cannabis use disorder (CUD) increase the risk of relapse and lacks effective treatments. The endocannabinoid enzyme fatty acid amide hydrolase (FAAH) may influence cannabis use and withdrawal, but the relationship between FAAH levels and withdrawal symptoms remains unclear. This study aims to investigate changes in FAAH levels during short-term abstinence from cannabis and their relationship with withdrawal symptoms. FAAH levels were measured in whole-brain regions of interest using positron emission tomography (PET) with the FAAH-specific probe [11C]CURB. An irreversible two-tissue compartment model determined [11C]CURB binding. Participants with CUD were scanned once after overnight abstinence (T1) and ~3-7 days after monitored last use (T2). FAAH polymorphism (rs324420) was determined from blood samples, and mood, cognition, withdrawal symptoms, and craving were assessed. In a sample of 14 participants (N = 17 prior to attrition) who completed both scans, FAAH binding in whole-brain increased between T1 and T2 (n = 14; %ΔFAAH = 10%; p = 0.003), with the largest change in the ventral striatum (11%, p = 0.026). Increases in FAAH (%ΔFAAH whole-brain) were significantly associated with longer cannabis abstinence, greater baseline depression severity, and tendency to act without thinking (p < 0.001). Short-term cannabis abstinence is associated with increases in brain FAAH levels. These changes are linked to traits and symptoms associated with relapse vulnerability, including negative mood and impulsivity. These preliminary findings suggest that FAAH may play a key role in the neurobiological response to short-term abstinence and could represent a potential target for interventions. **Primary Source & Scope:** Published in *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* (2026Oct) conducted by Claudia Poluga, Shahtaj S Dheda, Nadia Boachie, Tina McCluskey et al.. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42106478/) | **Primary Record:** DOI: 10.1038/s41386-026-02438-7 | PMID: 42106478 How Strong Is This Evidence? This is a small longitudinal PET study with 14 paired-scan completers, using a FAAH-specific tracer and an irreversible two-tissue compartment model. The within-person whole-brain increase was statistically significant (approximately 10%, p = 0.003), but confidence intervals and detailed statistical procedures are absent from the supplied abstract. Evidence is preliminary for an abstinence-associated biological change and insufficient for treatment efficacy or individual prediction. Where This Paper Deserves Skepticism Three of 17 participants did not complete both scans, and the later scan’s variable timing could influence both measured changes and their associations. The supplied abstract does not describe a repeated-scan control group, multiplicity correction, or adjustment for possible influences such as tobacco use, medication exposure, psychiatric conditions, and cannabis exposure patterns. Although FAAH genotype was measured, its role in the analyses is unclear, and models involving several predictors in only 14 participants may be unstable. What This Paper Does Not Show This study does not prove that increased FAAH binding causes withdrawal, predicts relapse, or indicates permanent brain damage. It does not establish a safe or effective FAAH-targeted treatment, a preferred cannabis dose or formulation, or a regulatory basis for clinical use of this imaging measure. How This Fits With the Broader Clinical Conversation Cannabis abstinence research examines several interconnected processes, including cannabinoid receptor adaptations, stress responses, sleep disruption, and reward-related behavior. FAAH imaging adds a distinct view of endogenous lipid signaling rather than replacing those other explanations. Interest in FAAH inhibition reflects the possibility of altering anandamide signaling without directly reproducing THC exposure. However, target plausibility, brain binding, symptom improvement, and sustained abstinence are separate evidentiary steps. Safety and effectiveness must be evaluated for each intervention rather than inferred from an observational scan. This paper fits best as an early mechanistic contribution. Larger longitudinal studies and controlled treatment trials are needed before the finding can move from biological explanation to patient-specific decision-making. Editorial Commentary *The approximately 10% whole-brain increase is the paper’s central contribution. Paired imaging makes the observation more informative than a single comparison between different people, but it remains a short-term biomarker finding in 14 participants. It should not be converted into a claim that an enzyme causes withdrawal or that inhibiting it will prevent relapse.* *The depression and impulsivity associations deserve careful replication. These characteristics are clinically important regardless of imaging, yet their relationship to FAAH could reflect shared influences, timing, or unstable estimates in a small sample. The supplied abstract does not establish a direct association between FAAH change and withdrawal severity.* *The practical response is better symptom assessment and support during cessation, not a new cannabis formulation or diagnostic scan. Progress would mean showing that this signal predicts meaningful outcomes or identifies a treatment that safely improves them.* What a Careful Reader Should Take Away Use these findings to support a measured discussion of biological changes during early abstinence, not to select cannabis products or experimental treatments. Patients struggling with cessation should seek individualized symptom assessment, mood screening, and structured follow-up. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🛡️Use Disorder](https://cedclinic.com/ask)[🧠Anxiety and Mood](https://cedclinic.com/ask)[⚖️Dosing](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Clinical Study Navigating biomedical publications regarding PET imaging of FAAH in chronic Cannabis users requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **Critical Rule**Separate the paired whole-brain result in 14 completers from the regional and symptom-trait associations; check confidence intervals, model complexity, and multiple-comparison handling in the full paper. **Critical Rule**Treat [11C]CURB binding as a model-dependent FAAH imaging measure, not a direct assay of anandamide levels, brain injury, or withdrawal severity. **Critical Rule**Check whether scan timing, genotype, attrition, and co-occurring exposures were addressed, and whether any actual withdrawal or relapse outcome supports the proposed clinical implications. Key Evaluation Question Does the FAAH binding increase reproducibly track clinically meaningful withdrawal or future relapse, beyond abstinence duration and baseline patient characteristics? The Patient Question What support and follow-up would help manage my sleep, mood, and cravings during cannabis reduction or cessation? The Bottom Line A small paired PET study detected increased FAAH binding during early abstinence, but clinical prediction and treatment implications remain unproven. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis The strongest finding is the within-person rise in whole-brain FAAH binding: approximately 10% across two scans in 14 completers, with p = 0.003. Repeated measurements reduce some differences between participants, allowing the study to detect a short-term biological change during abstinence. The ventral striatum showed the largest reported regional increase, 11%, with p = 0.026. Regional findings require particular caution because the supplied abstract does not describe correction for multiple comparisons. Statistical significance also does not establish that the change is clinically important. The reported associations with depression, impulsivity, and abstinence duration are hypothesis-generating. Without confidence intervals, detailed models, or a demonstrated relationship to actual relapse, their precision and clinical predictive value remain uncertain. Lens takeawayThe imaging signal is meaningful for research, but its clinical significance remains unproven. #### Patient Communication Patients can understand this study as evidence that an aspect of brain endocannabinoid biology changes during the first days without cannabis. It does not show that stopping cannabis damages the brain, that everyone experiences the same change, or that a scan can explain an individual patient’s symptoms. The useful clinical conversation concerns sleep, irritability, anxiety, mood, craving, and available support. Depression and impulsivity deserve attention because they can complicate cessation, not because this study establishes an enzyme-based diagnosis. Severe depression, suicidal thoughts, or inability to function warrants prompt clinical assessment regardless of the presumed relationship to withdrawal. Open and transparent discussions with healthcare providers help clarify realistic treatment timelines, administration methods, and appropriate product selection. Structured clinical dialogue around dosing titration, adverse effect thresholds, and realistic time horizons prevents misunderstandings while elevating the standard of care. Lens takeawayExplain withdrawal supportively, assess mood directly, and avoid interpreting scans as individual diagnoses. #### Dosing & Formulations This was an imaging study, not a comparison of THC doses, CBD ratios, routes of administration, or tapering schedules. Its findings cannot identify a preferred formulation for withdrawal or establish whether gradual reduction is better than abrupt cessation. A 10% increase in tracer binding is not a 10% change in cannabis requirements. FAAH acts on endogenous lipid signaling molecules, including anandamide; the measured signal does not translate directly into a replacement dose of THC or CBD. For patients using cannabis medically, a cessation plan should consider the treated condition, current exposure, psychiatric history, and other medications. Changing products solely to manipulate presumed FAAH activity would go beyond these data. Any medication-based withdrawal strategy requires its own clinical evidence and individualized assessment. Individualized dose titration, documented cannabinoid ratios, and monitored therapeutic responses remain essential for maximizing clinical benefit while minimizing adverse side effects. Lens takeawayNo THC dose, CBD ratio, or tapering schedule can be derived from this study. #### Safety & Side Effect Profile The study does not establish the safety of a FAAH inhibitor because participants were not described as receiving one. A biological target can be scientifically plausible without being a safe or effective treatment, and different investigational compounds cannot be treated as interchangeable. Cannabis withdrawal commonly involves disrupted sleep, irritability, anxiety, and reduced appetite. The clinical priority is symptom assessment, psychiatric safety, and support for maintaining the patient’s chosen reduction or cessation goal. Substituting alcohol, sedatives, or unregulated products can introduce additional harms that this PET study did not evaluate. Lens takeawayA plausible enzyme target does not justify self-treatment with experimental or unregulated products. #### Regulatory & Policy Dynamics These findings support further investigation of cannabis withdrawal biology, not a change in prescribing rules or product labeling. A small observational imaging study cannot establish a drug indication, validate a commercial withdrawal claim, or demonstrate that an intervention meets regulatory standards. Specialized FAAH PET imaging is a research method here. The supplied abstract offers no evidence that routine scanning improves patient outcomes or is cost-effective. Access to practical care should not depend on access to this technology. Policy discussions should distinguish a legitimate unmet treatment need from premature commercialization. Better access to behavioral treatment, psychiatric assessment, and follow-up can be pursued without treating this biomarker as ready for clinical deployment. Lens takeawaySupport withdrawal care and rigorous research without promoting an unvalidated clinical imaging service. #### Mechanisms & Physiology FAAH, fatty acid amide hydrolase, helps break down anandamide and other fatty acid amides. Anandamide participates in endocannabinoid signaling, which intersects with mood, stress regulation, and reward processing. That makes FAAH biologically relevant to questions about cannabis cessation. The researchers used [11C]CURB PET and an irreversible two-tissue compartment model to estimate FAAH binding. This is an indirect, model-dependent imaging measure. It is not a direct measurement of anandamide concentrations, moment-to-moment enzyme activity, or every component of the [endocannabinoid system](https://cedclinic.com/cbd-gummies-diabetes-management-evidence-safety/). Higher binding during abstinence is compatible with a change in FAAH availability, but the downstream signaling consequences were not demonstrated here. The rs324420 FAAH variant was measured because genetic variation can influence FAAH biology. The supplied abstract does not explain how genotype was incorporated into the reported analyses. Investigating receptor affinities, pharmacokinetic pathways, and cellular interactions clarifies the biological mechanisms underlying observed clinical outcomes. Lens takeawayFAAH binding offers a biological clue, not a complete map of withdrawal physiology. #### Research Limitations Only 14 of 17 participants completed both scans. In a sample this small, individual observations can strongly influence correlations, and attrition may matter if noncompleters differed in withdrawal severity or other characteristics. The supplied abstract does not provide enough information to judge that possibility. The later scan occurred approximately 3 to 7 days after monitored last use, rather than at one fixed interval. Abstinence duration itself was associated with binding change. No repeated-scan comparison group is described, limiting separation of abstinence effects from other time-related influences. Confidence intervals, model specifications, multiplicity procedures, and details of possible confounders are not supplied. Baseline depression and impulsivity associations do not demonstrate symptom causation, and the abstract does not report a significant direct relationship between FAAH change and withdrawal severity. Lens takeawaySmall numbers, variable scan timing, and incomplete methodological detail limit causal conclusions. #### Future Outlook A useful next study would enroll a larger, more diverse cohort, standardize scan timing, and follow participants beyond the first abstinence week. Repeated comparison scans would help distinguish abstinence-associated changes from measurement variation. Serial symptom assessments and prospective relapse outcomes could test whether FAAH binding adds clinically useful information. Treatment trials would answer a different question: whether changing FAAH activity improves withdrawal, retention in care, or sustained abstinence without unacceptable harms. Biomarker change alone would not establish benefit. Replication, prespecified analyses, transparent uncertainty estimates, and compound-specific safety evaluation should precede claims that this pathway can guide routine treatment. Future prospective investigations with standardized formulations and long-term follow-up will provide critical clarity as clinical evidence matures. Lens takeawayFuture research must connect the imaging signal to patient outcomes and treatment safety. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Brain+FAAH+Binding+Rises+During+Early+Cannabis+Abstinence+in+a+Small+PET+Study&url=https%3A%2F%2Fcedclinic.com%2Fced-brain-faah-binding-rises-during-ear-2026-10-07%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-brain-faah-binding-rises-during-ear-2026-10-07%2F) [BlueSky](https://bsky.app/intent/compose?text=Brain+FAAH+Binding+Rises+During+Early+Cannabis+Abstinence+in+a+Small+PET+Study%20https%3A%2F%2Fcedclinic.com%2Fced-brain-faah-binding-rises-during-ear-2026-10-07%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: PET imaging of FAAH in chronic Cannabis users: longitudinal assessment during short-term abstinence.](https://pubmed.ncbi.nlm.nih.gov/42106478/) Related Reading at CED ClinicContinue exploring the evidence[PP-01 for Cannabis Withdrawal: What a 14-Person Trial Found](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/) More on this topic: Clinical trial data evaluating pharmacological interventions and supportive care for cannabis withdrawal. [More on this topic: Withdrawal management](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/)[Cannabis Use Disorder Is Rising Among US Adults](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) More on this topic: Epidemiological evaluation of diagnostic trends, screening tools, and evidence-based patient counseling. [More on this topic: CUD trends & screening](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/)[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia. [More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) ## Frequently Asked Questions What did this study actually find? Among 14 participants with cannabis use disorder who completed both scans, whole-brain FAAH binding increased approximately 10% during short-term abstinence (p = 0.003). The largest reported regional increase was in the ventral striatum, at 11% (p = 0.026). What is FAAH? FAAH is an enzyme that breaks down anandamide and other fatty acid amides. It influences endogenous signaling systems, but measuring FAAH binding does not directly measure all endocannabinoid activity. Does this prove that FAAH causes cannabis withdrawal? No. The study identified an imaging change during abstinence and associations with several characteristics. It did not establish that FAAH changes caused withdrawal symptoms. Does the finding mean abstinence damages the brain? No. A change in enzyme-related tracer binding is not evidence of brain injury. The study does not establish whether the observed change is adaptive, harmful, or clinically neutral. Did the researchers show who would relapse? No relapse prediction result is reported in the supplied abstract. Depression and impulsivity may be relevant to relapse vulnerability, but their association with FAAH change does not validate an individual risk test. Can a PET scan help choose my cannabis dose? This study provides no basis for that use. It did not test dose selection, THC-to-CBD ratios, or whether PET-guided decisions improve outcomes. Should someone take CBD or a FAAH inhibitor for withdrawal based on this paper? No treatment recommendation can be derived from these findings. CBD and investigational FAAH inhibitors require separate evidence of efficacy, dosing, interactions, and safety. What should patients do if withdrawal symptoms are difficult? Discuss symptoms with a clinician, especially sleep disruption, anxiety, depression, and strong cravings. Behavioral support and planned follow-up can help; suicidal thoughts or severe psychiatric deterioration require urgent assessment. How reliable are results from 14 participants? The paired design supports detection of within-person change, and the whole-brain result was statistically significant. However, the small sample limits precision, generalizability, and confidence in multivariable associations, particularly without full methodological details. Do these findings apply to all medical cannabis patients? Not necessarily. Participants had cannabis use disorder, and the supplied abstract does not establish applicability across medical indications, exposure patterns, ages, or psychiatric histories. Medical cannabis use and cannabis use disorder are not interchangeable categories. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).